Products
PlantForm’s vivoXPRESS® plant-based technology platform is designed to deliver a wide range of biopharmaceutical products, including therapeutic and medical countermeasure drugs. Our pipeline includes:
Biosimilar ranibizumab
PlantForm’s lead product is a biosimilar version of Roche’s age-related macular degeneration (AMD) drug Lucentis®, the brand name for ranibizumab.
Lucentis® had sales of C$4.8 billion in 2015 and begins to lose patent protecting in 2020 in the United States and 2022 in Europe. A treatment course with Lucentis® can cost as much as $30,000 per patient. PlantForm expects its plant-based production system will lower manufacturing costs by as much as 90 per cent.
Laboratory studies have shown that PlantForm’s biosimilar ranibizumab antibody drug is produced at commercially viable production rates and interacts with the receptor-binding site on VEGF-A as expected. Human clinical trials are expected to begin in the next 18-24 months.
PlantForm expects to launch biosimilar ranibizumab, in partnership with a pharmaceutical company, in world markets in 2027. PlantForm management estimates the total market potential for all biosimilar AMD products will be $3.5 billion a year by 2024.
PlantForm is also developing biobetter versions of two additional biologic drugs which are recombinant replacement versions of plasma-derived drugs
Biosimilar pembrolizumab
PlantForm is advancing a plant-produced biosimilar pembrolizumab (Keytruda®) with the Ministry of Health in Brazil (Fiocruz) for market entry in 2028.
PhD9 Antibody for ricin exposure
PlantForm subsidiary AntoXa Corporation is using the vivoXPRESS® system to produce an innovator antibody being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure. The PhD9 antibody drug candidate developed by DRDC prevents ricin from penetrating cells.
Recombinant butyrylcholinesterase (rBuChE)
Butyrylcholinesterase (BuChE) is an enzyme that has been developed as a bioscavenger to provide prophylactic protection against nerve agents such as sarin gas. PlantForm, through its subsidiary AntoXa Corporation under contract with DRDC, continues to advance the BuChE program begun more than a decade ago with the U.S. Defense Advanced Research Projects Agency (DARPA).
Hemopexin
Hemopexin is an innovative enzyme drug that shows promise for treating respiratory damage caused by sickle cell disease and exposure to toxic halogens such as chlorine gas. Research by the University of Alabama at Birmingham in collaboration with PlantForm and AntoXa scientists has demonstrated that recombinant human hemopexin, generated in plants using the vivoXPRESS® platform, was equally effective in reversing lung and mitochondrial injury caused by exposure to chlorine gas.
Antibodies for HIV/AIDS
PlantForm is developing innovator antibodies for the treatment of human immunodeficiency virus (HIV), with funding from the Government of Canada and the Bill & Melinda Gates Foundation through NRC-IRAP's Canadian HIV Technology Development (CHTD) Program. These antibodies fight infection by disrupting the virus's method of entry into human CD4+ lymphocytes (T-cells).
Partnerships
PlantForm is interested in establishing partnerships with other companies to develop additional targeted biosimilar and innovator drugs. Learn more about our CDMO services.